alpha-amanitin-conjugated anti-epithelial cell adhesion molecule antibody (Heidelberg Pharma)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namealpha-amanitin-conjugated anti-epithelial cell adhesion molecule antibody (Heidelberg Pharma)

Drug Alias Namealpha-amanitin-conjugated anti-epithelial cell adhesion molecule antibody (University of Texas MD Anderson Cancer Center)EPCAM-ATAC

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionDNA-directed RNA polymerase II subunit RPB1 inhibitorsEpithelial cell adhesion molecule inhibitors

TargetsDNA-directed RNA polymerase II subunit RPB1Epithelial cell adhesion molecule

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe University Of Texas MD Anderson Cancer Center Heidelberg Pharma AG

Active IndicationsN/A

Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A